Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Debu Tripathy, MD, introduces new information onCDK4/6 inhibitors discussed at ASCO20

Dr. Tripathy, Chair, Breast Medical Oncology, MD Anderson Cancer Center, introduces new information regarding CDK4/6 inhibitors for hormone receptor positive breast cancer discussed at ASCO20

Tags: ASCO Conference CoverageBreast

Published: 17 June 2020

Recent Videos

video

Zarnie Lwin, MBBS, FRACP, on the safety and efficacy of combining TKIs with checkpoint inhibitors

Dr. Lwin, Associate Professor, University of Queensland, Consultant Medical Oncologist, Cancer Care Services, Royal Brisbane and Women’s Hospital, provides perspective ...

video

Andrew Schmidt, MD, speculates on next steps for the COVID-19 and Cancer Outcomes study (CCOS)

Dr. Schmidt, Medical Oncologist, Research Fellow in Medicine, Dana Farber Cancer Institute, considers the next steps in the COVID-19 and ...

video

Cristina Suárez, MD, on what physicians should consider when combining checkpoint inhibitors & TKIs

Dr. Suárez, Physician-Scientist, Medical Oncologist, Vall d´Hebron University Hospital (HUVH), Barcelona, Spain, considers the challenges and/or adverse events to be ...

video

Andrew Schmidt, MD, regarding the predicted surge in the number of cancer patients due to COVID-19

Dr. Schmidt, Medical Oncologist, Research Fellow in Medicine, Dana Farber Cancer Institute, offers opinion on the predicted surge in the ...

video

Cristina Suárez, MD, on patient subtype responses to combo nivolumab + cabozantinib in 1st line RCC

Dr. Suárez, Physician-Scientist, Medical Oncologist, Vall d´Hebron University Hospital (HUVH), Barcelona, Spain, considers whether there are patient subtypes more likely ...

video

Cristina Suárez, MD, offers opinion on whether the CheckMate 9ER trial is practice-changing

Dr. Suárez, Physician-Scientist, Medical Oncologist, Vall d´Hebron University Hospital (HUVH), Barcelona, Spain, offers opinion on whether the CheckMate 9ER trial ...

video

Andrew Schmidt, MD, on interventions that may help correct the disparity in cancer care disruptions

Dr. Schmidt, Medical Oncologist, Research Fellow in Medicine, Dana Farber Cancer Institute, shares examples of potential interventions that may help ...

video

Cristina Suárez, MD, compares the control arm of CheckMate 9ER with current 1st line RCC regimens

Dr. Suárez, Physician-Scientist, Medical Oncologist, Vall d´Hebron University Hospital (HUVH), Barcelona, Spain, discusses the control arm of the CheckMate 9ER ...

video

Andrew Schmidt, MD, on the nature of COVID-19 cancer care disruptions among minority populations

Dr. Schmidt, Medical Oncologist, Research Fellow in Medicine, Dana Farber Cancer Institute, speculates as to why COVID-19 may have caused ...

video

Cristina Suárez, MD, elaborates on the outcomes of the CheckMate 9ER study presented at ESMO 2020

Dr. Suárez, Physician-Scientist, Medical Oncologist, Vall d´Hebron University Hospital (HUVH), Barcelona, Spain, discusses the outcomes of the CheckMate 9ER study ...

Related Videos

video-image

Andrew Schmidt, MD, regarding the predicted surge in the number of cancer patients due to COVID-19

video-image

Cristina Suárez, MD, on what physicians should consider when combining checkpoint inhibitors & TKIs

video-image

Andrew Schmidt, MD, speculates on next steps for the COVID-19 and Cancer Outcomes study (CCOS)

video-image

Cristina Suárez, MD, on the promise of I-O in advanced renal cell carcinoma

video-image

Zarnie Lwin, MBBS, FRACP, on the safety and efficacy of combining TKIs with checkpoint inhibitors

video-image

Andrew Schmidt, MD, regarding the COVID-19 and Cancer Outcomes Study (CCOS) presented at ESMO 2020

video-image

Cristina Suárez, MD, elaborates on the outcomes of the CheckMate 9ER study presented at ESMO 2020

video-image

Andrew Schmidt, MD, on the nature of COVID-19 cancer care disruptions among minority populations

video-image

Cristina Suárez, MD, compares the control arm of CheckMate 9ER with current 1st line RCC regimens

video-image

Andrew Schmidt, MD, on interventions that may help correct the disparity in cancer care disruptions

video-image

Cristina Suárez, MD, offers opinion on whether the CheckMate 9ER trial is practice-changing

video-image

Cristina Suárez, MD, on patient subtype responses to combo nivolumab + cabozantinib in 1st line RCC

video-image

Giuseppe Giaccone, PhD, MD, speculates on next steps in the development of Tedopi (OSE2101)

video-image

Maha Hussain, MD, considers the role of homologous recombination repair in the management of mCRPC

video-image

Erika Hamilton, MD, considers the comparison between the monarchE and PALLAS clinical trials

video-image

Pasi A. Jänne, MD, PhD, shares data from ESMO 2020 investigating mobocertinib

video-image

Erika Hamilton, MD, shares thoughts on tolerability in high risk early breast cancer patients

video-image

Erika Hamilton, MD, on how CDK4/6 inhibitors transformed the management of metastatic breast cancer

video-image

Giuseppe Giaccone, PhD, MD, regarding the mechanism of action of Tedopi (OSE2101)

video-image

Maha Hussain, MD, shares the design of the Phase III PROfound study in mCRPC